In Vivo Formation of 8-Iso-Prostaglandin F2α and Platelet Activation in Diabetes Mellitus

Background—Diabetes mellitus (DM) is associated with enhanced lipid peroxidation and persistent platelet activation. We tested the hypothesis that the in vivo formation of the F2-isoprostane 8-iso-prostaglandin (PG)F2α, a bioactive product of arachidonic acid peroxidation, is enhanced in DM and contributes to platelet activation. Methods and Results—Urine samples were obtained from 85 diabetic patients and 85 age- and sex-matched healthy subjects for measurement of immunoreactive 8-iso-PGF2α and 11-dehydro-thromboxane B2 (TXM), an in vivo index of platelet activation. Sixty-two had non–insulin-dependent (NID)DM, and 23 had insulin-dependent (ID) DM. Vitamin E supplementation, metabolic control, and cyclooxygenase inhibitors were used to investigate the mechanisms of formation of 8-iso-PGF2α in this setting. Urinary 8-iso-PGF2α excretion was significantly higher (P=0.0001) in NIDDM patients (419±208 pg/mg creatinine; range 160 to 1014) than in age-matched control subjects (208±92; 41 to 433). Urinary 8-iso...

[1]  G. Davı̀,et al.  Antiplatelet agents in the prevention of diabetic vascular complications. , 1993, Diabetes/metabolism reviews.

[2]  J. Morrow,et al.  The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. , 1992, Prostaglandins.

[3]  G. Davı̀,et al.  Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. , 1997, Circulation.

[4]  G. FitzGerald,et al.  Local Amplification of Platelet Function by 8-Epi Prostaglandin F2α Is Not Mediated by Thromboxane Receptor Isoforms* , 1996, The Journal of Biological Chemistry.

[5]  J. Morrow,et al.  Glomerular actions of a free radical-generated novel prostaglandin, 8-epi-prostaglandin F2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. , 1992, The Journal of clinical investigation.

[6]  B. Halliwell,et al.  Relationships between plasma measures of oxidative stress and metabolic control in NIDDM , 1997, Diabetologia.

[7]  D. Betteridge,et al.  Plasma 8‐epi‐PGF2α levels are elevated in individuals with non‐insulin dependent diabetes mellitus , 1995, FEBS letters.

[8]  A. Jenkins,et al.  LDL From Patients With Well-Controlled IDDM Is Not More Susceptible to In Vitro Oxidation , 1996, Diabetes.

[9]  G. Davı̀,et al.  In Vivo Formation of 8-Epi-Prostaglandin F2α Is Increased in Hypercholesterolemia , 1997 .

[10]  A. Manto,et al.  Defective Plasma Antioxidant Defenses and Enhanced Susceptibility to Lipid Peroxidation in Uncomplicated IDDM , 1997, Diabetes.

[11]  P. Halushka,et al.  Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. , 1994, The Journal of pharmacology and experimental therapeutics.

[12]  J. Berliner,et al.  The role of oxidized lipoproteins in atherogenesis. , 1996, Free radical biology & medicine.

[13]  I. Hirsch,et al.  Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM , 1994, Diabetes.

[14]  J. Morrow,et al.  A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  U. Garbin,et al.  E-Selectin plasma concentration is influenced by glycaemic control in NIDDM patients: possible role of oxidative stress , 1997, Diabetologia.

[16]  G. FitzGerald,et al.  Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  G. FitzGerald,et al.  Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. , 1995, The Journal of pharmacology and experimental therapeutics.

[18]  P. Koudstaal,et al.  Platelet activation and lipid peroxidation in patients with acute ischemic stroke. , 1997, Stroke.

[19]  G. Davı̀,et al.  Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.

[20]  C. Patrono,et al.  Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease , 1998, Thrombosis and Haemostasis.

[21]  J. Morrow,et al.  Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. , 1995, The New England journal of medicine.

[22]  A. de Leiva,et al.  Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control , 1996, Diabetologia.

[23]  A. Lechi,et al.  The F2-isoprostane 8-epiprostaglandin F2alpha increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Reilly,et al.  Modulation of oxidant stress in vivo in chronic cigarette smokers. , 1996, Circulation.

[25]  J. Morrow,et al.  Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. , 1993, The Journal of biological chemistry.

[26]  L. Lanting,et al.  Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. , 1996, The American journal of physiology.

[27]  G. FitzGerald,et al.  Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. , 1987, Biochimica et biophysica acta.

[28]  T. Ishikawa,et al.  Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus. , 1997, Arteriosclerosis, thrombosis, and vascular biology.